Ashley Dombkowski, PhD is a Managing Director with Bay City Capital and has been with the firm since 2013. She has nearly 20 years of experience as an investor, operating executive, and entrepreneur in the healthcare field. Prior to joining Bay City, she served as Chief Business Officer and Vice President of Operations for 23andMe, where she oversaw the company’s finance and operations activities and had responsibility for the company’s long term business strategy focused on database growth plans, R&D productivity, and profitability. Prior to joining 23andMe, she was a Managing Director with venture capital firm MPM Capital where she also served as a member of the firm’s Investment Committee. During her years at MPM she focused on developing innovative biotechnology, medical device, and healthcare IT companies, including companies such as 23andMe, Adolor, Alnara, BioVitrum, Epizyme, iPierian, Neosil, Nevro, Rigel, and Tercica. Prior to this, she was a Healthcare Equity Analyst for hedge fund Tiger Management L.L.C. and for institutional asset management firm Dresdner RCM Global Investors. Dr. Dombkowski holds a PhD in Mathematics from Rice University and received her BA in Mathematics from Wellesley College.
| Types | Person, Business Person |
| Gender | Female |